Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
By United One News · AI-generated summary of 3 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
- Pfizer has released phase 2 clinical trial data for its 25-valent pneumococcal vaccine.
- The company shared the findings regarding the vaccine's performance during the study.
- Further details from the trial evaluation were not provided in the announcement.
Covered by 3 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
Timeline
First to report: Globenewswire_fr (); 3 articles from 3 outlets so far.
Who is covering this story
- Center (3): Globenewswire_fr, Investing Uk, Seeking Alpha
Sources
- NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma — Globenewswire_fr (center, AI-estimated) ·
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine — Investing Uk (center, AI-estimated) ·
- Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript — Seeking Alpha (center, AI-estimated) ·